Vertex Reports Second Quarter 2026 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Vertex Pharma (VRTX) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY26 Revenue Guidance
August 3, 2026 4:02 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $4.73, $0.01 better than the analyst estimate of $4.72. Revenue for the quarter came in at $3.33 billion versus the consensus estimate of $3.22 billion.
GUIDANCE:
Vertex Pharma sees FY2026 revenue of $13.1-13.2 billion, versus the consensus of... More
